3/19/2019 7:13:26 AM
Iterum Therapeutics Gets QIDP For Oral And IV Sulopenem In Four Addl Indications As Well As Fast Track Designation
11/14/2018 7:17:45 AM
Iterum Therapeutics Q3 Net Loss $24.9 Mln Vs. Net Loss Of $8.2 Mln Prior Year
10/5/2018 8:06:54 AM
Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem At IDWeek 2018
9/18/2018 8:07:37 AM
Iterum Begins Second And Third Of Three Planned Phase 3 Clinical Trials For Sulopenem
8/14/2018 7:37:41 AM
Iterum Therapeutics Q2 Net Loss $15.7 Mln Vs, Loss $6.3 Mln Prior Year